Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cystic Fibrosis Pulmonary Exacerbation Clear all

Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection
Interventions: Ceftolozane/Tazobactam; Drug
Lead sponsor: Joseph L. Kuti, PharmD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 2 more

Conditions: Cystic Fibrosis-related Diabetes, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis in Children
Interventions: Sensor Augmented Pump Therapy, Standard of Care with CGM; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo, Tobramycin solution for inhalation; Drug
Lead sponsor: Bonnie Ramsey; Other
Eligibility: 6 Months to 18 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 12 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more

Conditions: Cystic Fibrosis Pulmonary Exacerbation
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions: Beta-lactam antibiotic, Aminoglycoside; Drug
Lead sponsor: Chris Goss; Other
Eligibility: 6 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 59
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 49 more

Conditions: Cystic Fibrosis
Interventions: Early Intervention; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions: Sodium Fusidate, Placebo; Drug
Lead sponsor: Aceragen; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 25
States / cities: Gainesville, Florida • Orlando, Florida • Pensacola, Florida + 22 more

Conditions: Cystic Fibrosis
Interventions: Xylitol, Hypertonic saline; Drug
Lead sponsor: Joseph Zabner; Other
Eligibility: 12 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cystic Fibrosis
Interventions: Vitamin D3, Placebo; Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis
Interventions: Lung Clearance Index, MRI with PFP; Device · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cystic Fibrosis
Interventions: Immediate Antibiotics, Tailored Treatment; Other
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 7 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 18 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Cystic Fibrosis
Interventions: Standard of care IV antibiotic(s); Drug
Lead sponsor: Chris Goss; Other
Eligibility: 18 Years and older
Enrollment: 982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 57
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 52 more

Conditions: Cystic Fibrosis
Interventions: Home lung function and symptom monitoring; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Cystic Fibrosis
Interventions: Cysteamine, Placebo Oral Capsule; Drug
Lead sponsor: NovaBiotics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more

Conditions: Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions: meropenem; Drug
Lead sponsor: Joseph Kuti; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Cystic Fibrosis
Interventions: Aerobic exercise, Resistance exercise, Flexibility and postural exercise, Balance exercise; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 6 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bronchiectasis
Interventions: Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Peoria, Arizona • Fountain Valley, California • La Jolla, California + 19 more

Conditions: Cystic Fibrosis, Pulmonary Exacerbation
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Ototoxicity
Interventions: Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: CMS, Placebo; Drug · Other
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Newport Beach, California • Palm Springs, California • Reseda, California + 22 more

Conditions: Cystic Fibrosis
Interventions: Sit to stand test; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 35 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation

Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF

Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects

Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Pilot Study

Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation

Standardized Treatment of Pulmonary Exacerbations II

Early Intervention in Cystic Fibrosis Exacerbation

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation